Fig. 6

In vitro assessment of human epidermal growth factor receptor 2-targeted and adaptive tumor-infiltrating lymphocyte therapy. a Patient-derived xenograft organoid (PDXO) and autologous T-cell coculture system flowchart. b HER2-mutation (I655V: 1963A > G) found in primary tumor, PDX, and PDXO. c Histology of PDX and PDXO from patient CAT061 (scale bar, 50 μm). d Neratinib sensitivity of PDXO from patient CAT061 was determined. The average half-maximal inhibitory concentration from three separate experiments (n = 3) for CAT061 PDXO was 40.91 nM. e CAT061 PDXO and TIL cocultures were treated with DMSO or neratinib for 24 h. Mannose-6-phosphate receptor on the surface of CAT061 PDXO tumor cells was determined by flow cytometry. (Student’s t-test, p = 0.0102) f Cytotoxicity against PDXO cells was measured in a standard 4-h lactate dehydrogenase release assay. g Granzyme B expression in CD4⁺ and CD8⁺ T cells of the PDXO and TIL cocultures was determined by flow cytometry (two-way analysis of variance). ^*p < 0.05, ^**p < 0.01, NS, not significant